MX2021015545A - Moduladores de cot y metodos de uso de estos. - Google Patents
Moduladores de cot y metodos de uso de estos.Info
- Publication number
- MX2021015545A MX2021015545A MX2021015545A MX2021015545A MX2021015545A MX 2021015545 A MX2021015545 A MX 2021015545A MX 2021015545 A MX2021015545 A MX 2021015545A MX 2021015545 A MX2021015545 A MX 2021015545A MX 2021015545 A MX2021015545 A MX 2021015545A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- cot
- modulators
- cot modulators
- manufacture
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000001685 thyroid gland Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
La presente divulgación se refiere en general a moduladores de Cot (cáncer Osaka tiroides) de la Fórmula genérica (I) y métodos de uso y fabricación de estos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962861390P | 2019-06-14 | 2019-06-14 | |
PCT/US2020/037214 WO2020252151A1 (en) | 2019-06-14 | 2020-06-11 | Cot modulators and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021015545A true MX2021015545A (es) | 2022-02-16 |
Family
ID=71950735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021015545A MX2021015545A (es) | 2019-06-14 | 2020-06-11 | Moduladores de cot y metodos de uso de estos. |
Country Status (21)
Country | Link |
---|---|
US (6) | US20220259234A1 (es) |
EP (2) | EP4375279A2 (es) |
JP (2) | JP7286813B2 (es) |
KR (2) | KR20230169422A (es) |
CN (3) | CN117946167A (es) |
AR (1) | AR119138A1 (es) |
AU (2) | AU2020290461B2 (es) |
BR (1) | BR112021025039A2 (es) |
CA (1) | CA3142478A1 (es) |
CL (2) | CL2021003336A1 (es) |
CO (1) | CO2021016834A2 (es) |
CR (1) | CR20210620A (es) |
DK (1) | DK3983064T3 (es) |
DO (1) | DOP2023000172A (es) |
FI (1) | FI3983064T3 (es) |
IL (3) | IL311531A (es) |
MX (1) | MX2021015545A (es) |
PE (1) | PE20220509A1 (es) |
SG (1) | SG11202113307TA (es) |
TW (2) | TWI770527B (es) |
WO (1) | WO2020252151A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114380799A (zh) | 2015-07-06 | 2022-04-22 | 吉利德科学公司 | Cot调节剂及其使用方法 |
TWI770527B (zh) * | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
WO2021202224A1 (en) * | 2020-03-30 | 2021-10-07 | Gilead Sciences, Inc. | Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
JP7446475B2 (ja) | 2020-04-02 | 2024-03-08 | ギリアード サイエンシーズ, インコーポレイテッド | Cot阻害剤化合物を調製するためのプロセス |
TW202304435A (zh) * | 2021-06-04 | 2023-02-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
CA3223412A1 (en) * | 2021-06-23 | 2022-12-29 | Erika BUTLER | Process for preparing egfr inhibitors |
US20240174702A1 (en) * | 2022-05-12 | 2024-05-30 | Gilead Sciences, Inc. | Solid forms of a compound for modulating cot |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3930837A (en) | 1971-12-31 | 1976-01-06 | Ici Australia Limited | 3-chloro-5-acetamidaisoquinoline as a herbicide |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4151298A (en) | 1977-01-10 | 1979-04-24 | Ciba-Geigy Corporation | Anthelmintic compositions |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
JP2634438B2 (ja) | 1988-07-26 | 1997-07-23 | 三井東圧化学株式会社 | 不斉ビスオキサゾリルピリジン誘導体およびその製造方法 |
DE4014171A1 (de) | 1990-05-03 | 1991-11-07 | Basf Ag | Cyanochinolinverbindungen |
GB9310700D0 (en) | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Novel composition |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
NZ503079A (en) | 1997-08-28 | 2002-07-26 | Nissan Chemical Ind Ltd | Cyanoacrylate-containing antibacterial and antifungal agents, algicides and antifouling agents |
JP5035813B2 (ja) | 1998-07-10 | 2012-09-26 | マサチューセッツ インスティテュート オブ テクノロジー | 金属用のリガンドおよびそれらに基づいて改善された金属触媒法 |
EA004427B1 (ru) | 1998-09-29 | 2004-04-29 | Уайт Холдингз Корпорейшн | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ |
WO2003080047A1 (en) | 2002-03-20 | 2003-10-02 | Bristol-Myers Squibb Company | Phosphate prodrugs of fluorooxindoles |
ES2297386T3 (es) | 2003-03-03 | 2008-05-01 | F. Hoffmann-La Roche Ag | Tetrahidroisoquinolinas 2,5-sustituidas para uso como moduladores de 5-ht6. |
AU2004267061A1 (en) | 2003-08-19 | 2005-03-03 | Wyeth Holdings Corporation | Process for the preparation of 4-amino-3-quinolinecarbonitriles |
US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
TW200529846A (en) | 2004-02-20 | 2005-09-16 | Wyeth Corp | 3-quinolinecarbonitrile protein kinase inhibitors |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
JP2008540656A (ja) | 2005-05-18 | 2008-11-20 | ワイス | Tpl2キナーゼの3−シアノキノリン阻害物質ならびにそれを製造および使用する方法 |
MX2007014258A (es) | 2005-05-18 | 2008-01-22 | Wyeth Corp | Inhibidores de 4,6-diamino-[1,7]naftiridin-3-carbonitrilo de la tpl2 cinasa y metodos de fabricacion y uso de los mismos. |
UA94246C2 (ru) | 2005-10-28 | 2011-04-26 | Эбботт Леборетриз | Производные индазола, которые ингибируют рецептор trpv1 |
CN101437519A (zh) | 2006-03-31 | 2009-05-20 | 艾博特公司 | 吲唑化合物 |
JP5599614B2 (ja) | 2006-11-09 | 2014-10-01 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
US8389544B2 (en) | 2007-01-17 | 2013-03-05 | The Hong Kong University Of Science And Technology | Isoquinolone compounds as subtype-selective agonists for melatonin receptors MT1 and MT2 |
GB0820856D0 (en) | 2008-11-14 | 2008-12-24 | Univ Leuven Kath | Novel inhibitors of flavivirus replication |
TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
GB0922302D0 (en) | 2009-12-22 | 2010-02-03 | Imp Innovations Ltd | Compounds |
EP2545187B1 (en) | 2010-03-09 | 2018-09-05 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
ES2773693T3 (es) | 2010-06-09 | 2020-07-14 | Tianjin Hemay Oncology Pharmaceutical Co Ltd | Derivados de cianoquinolina |
EP2708540B1 (en) | 2011-05-10 | 2018-07-25 | Kyowa Hakko Kirin Co., Ltd. | Pyrimido-diazepinone compound |
BR112014000267A2 (pt) | 2011-07-04 | 2016-09-20 | Bayer Ip Gmbh | utilização de isoquinolinonas, isoquinolinedionas, isoquinolinetrionas e dihidroisoquinolinonas substituídas ou, em cada caso, sais das mesmas como agentes ativos contra o stress abiótico em plantas |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
DK2772482T3 (en) | 2011-10-27 | 2016-06-06 | Taisho Pharmaceutical Co Ltd | azole derivative |
MX2020000331A (es) | 2011-11-11 | 2022-03-16 | Gilead Apollo Llc | Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos. |
UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
CN103483363B (zh) | 2012-06-13 | 2016-12-21 | 上海赛迦化工产品有限公司 | 多样性的手性氨基硼酸及其制备方法和应用 |
CN105142621A (zh) | 2012-10-24 | 2015-12-09 | 国家健康科学研究所 | 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂 |
CN103408572B (zh) | 2013-07-12 | 2015-12-02 | 上海工程技术大学 | 手性氨基硼酸衍生物及其制备方法和应用 |
CN108947867A (zh) | 2013-12-12 | 2018-12-07 | 卡利拉制药公司 | 双环烷基化合物及合成 |
EP3114107B1 (en) | 2014-03-07 | 2020-07-22 | Recurium IP Holdings, LLC | Propellane derivates and synthesis |
US9701661B2 (en) | 2014-07-11 | 2017-07-11 | Northwestern University | 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase |
EP3193855B1 (en) | 2014-09-17 | 2021-05-19 | Recurium IP Holdings, LLC | Bicyclic compounds |
BR112017005693A2 (pt) | 2014-09-24 | 2017-12-12 | Gilead Sciences Inc | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. |
MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
PL3237404T3 (pl) | 2014-12-23 | 2021-05-04 | Gilead Sciences, Inc. | Procesy wytwarzania inhibitorów ask1 |
AU2016205138A1 (en) | 2015-01-09 | 2017-07-13 | Gilead Apollo, Llc | ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
JP6580145B2 (ja) | 2015-01-16 | 2019-09-25 | スリーエム イノベイティブ プロパティズ カンパニー | グリッド出力を改善するグリッド行動を選択するためのシステム及び方法 |
NZ738538A (en) | 2015-07-06 | 2019-06-28 | Gilead Sciences Inc | 6-amino-quinoline-3-carbonitrils as cot modulators |
CN114380799A (zh) | 2015-07-06 | 2022-04-22 | 吉利德科学公司 | Cot调节剂及其使用方法 |
DK3398598T3 (da) | 2015-12-31 | 2022-07-11 | Hitgen Inc | Sulfonamidderivat og fremstillingsmetode og anvendelse deraf |
US10183951B2 (en) | 2016-03-02 | 2019-01-22 | Gilead Apollo, Llc | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof |
EP3473715B1 (en) | 2016-06-21 | 2021-08-04 | PHC Holdings Corporation | Catalase inhibitor and method for measuring analyte using catalase inhibitor |
WO2018005435A1 (en) | 2016-06-30 | 2018-01-04 | Gilead Sciences, Inc. | 4,6-diaminoquinazolines as cot modulators and methods of use thereof |
CN106512014A (zh) | 2016-10-27 | 2017-03-22 | 武汉大学 | 肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用 |
CN110382503B (zh) | 2017-03-03 | 2022-07-19 | 吉利德科学公司 | 制备acc抑制剂及其固体形式的方法 |
WO2018183193A1 (en) | 2017-03-28 | 2018-10-04 | Gilead Sciences, Inc. | Therapeutic combinations for treating liver diseases |
AU2018250614A1 (en) | 2017-04-12 | 2019-10-17 | Gilead Sciences, Inc. | Methods of treating liver disease |
WO2019071216A1 (en) | 2017-10-06 | 2019-04-11 | Gilead Sciences, Inc. | POLYTHERAPY COMPRISING AN ACC INHIBITOR |
CN108636625B (zh) * | 2018-03-13 | 2021-09-14 | 因诺弥斯特有限责任公司 | 多模式流体喷嘴 |
US11524005B2 (en) | 2019-02-19 | 2022-12-13 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
US20220143153A1 (en) | 2019-03-08 | 2022-05-12 | The Regents Of The University Of California | Compositions and methods for treating acne |
TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
WO2021202224A1 (en) | 2020-03-30 | 2021-10-07 | Gilead Sciences, Inc. | Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
JP7446475B2 (ja) | 2020-04-02 | 2024-03-08 | ギリアード サイエンシーズ, インコーポレイテッド | Cot阻害剤化合物を調製するためのプロセス |
TW202304435A (zh) * | 2021-06-04 | 2023-02-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
-
2020
- 2020-06-10 TW TW109119416A patent/TWI770527B/zh active
- 2020-06-10 TW TW111121600A patent/TW202235416A/zh unknown
- 2020-06-11 CN CN202410099826.1A patent/CN117946167A/zh active Pending
- 2020-06-11 PE PE2021002080A patent/PE20220509A1/es unknown
- 2020-06-11 EP EP24154495.6A patent/EP4375279A2/en active Pending
- 2020-06-11 CA CA3142478A patent/CA3142478A1/en active Pending
- 2020-06-11 DK DK20751726.9T patent/DK3983064T3/da active
- 2020-06-11 AU AU2020290461A patent/AU2020290461B2/en active Active
- 2020-06-11 SG SG11202113307TA patent/SG11202113307TA/en unknown
- 2020-06-11 AR ARP200101649A patent/AR119138A1/es unknown
- 2020-06-11 JP JP2021573842A patent/JP7286813B2/ja active Active
- 2020-06-11 MX MX2021015545A patent/MX2021015545A/es unknown
- 2020-06-11 IL IL311531A patent/IL311531A/en unknown
- 2020-06-11 BR BR112021025039A patent/BR112021025039A2/pt unknown
- 2020-06-11 US US17/618,696 patent/US20220259234A1/en active Pending
- 2020-06-11 CR CR20210620A patent/CR20210620A/es unknown
- 2020-06-11 KR KR1020237041219A patent/KR20230169422A/ko not_active Application Discontinuation
- 2020-06-11 IL IL299567A patent/IL299567B1/en unknown
- 2020-06-11 CN CN202410099768.2A patent/CN117946166A/zh active Pending
- 2020-06-11 WO PCT/US2020/037214 patent/WO2020252151A1/en unknown
- 2020-06-11 CN CN202080043370.7A patent/CN114026104B/zh active Active
- 2020-06-11 US US16/898,981 patent/US20210061831A1/en not_active Abandoned
- 2020-06-11 FI FIEP20751726.9T patent/FI3983064T3/fi active
- 2020-06-11 EP EP20751726.9A patent/EP3983064B1/en active Active
- 2020-06-11 KR KR1020227000961A patent/KR102609360B1/ko active IP Right Grant
- 2020-08-17 US US16/994,889 patent/US10947259B2/en active Active
-
2021
- 2021-01-29 US US17/162,754 patent/US11325930B2/en active Active
- 2021-11-22 IL IL288310A patent/IL288310A/en unknown
- 2021-12-13 CO CONC2021/0016834A patent/CO2021016834A2/es unknown
- 2021-12-13 CL CL2021003336A patent/CL2021003336A1/es unknown
-
2022
- 2022-04-07 US US17/715,366 patent/US11827662B2/en active Active
-
2023
- 2023-01-11 CL CL2023000112A patent/CL2023000112A1/es unknown
- 2023-03-27 JP JP2023049724A patent/JP2023076560A/ja active Pending
- 2023-08-29 DO DO2023000172A patent/DOP2023000172A/es unknown
- 2023-09-28 US US18/374,108 patent/US20240043458A1/en active Pending
-
2024
- 2024-04-02 AU AU2024202085A patent/AU2024202085A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551397A1 (en) | Cot modulators and methods of use thereof | |
CR20210620A (es) | Moduladores de cot y métodos de uso de los mismos | |
JOP20220008A1 (ar) | مثبطات parp1 | |
MX2017017124A (es) | 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot). | |
MX2020009347A (es) | Picolinamidas como fungicidas. | |
PH12015502161A1 (en) | Therapeutic compounds and compositions | |
MX2019015744A (es) | Composiciones farmaceuticas. | |
PH12020500655A1 (en) | Compounds | |
MX2020010951A (es) | Anticuerpos anti-hla-g y utilizacion de los mismos. | |
PH12017500737A1 (en) | Kcnq2-5 channel activator | |
MX2021010916A (es) | Inhibidores rad51. | |
UA115683C2 (uk) | Комбінована терапія для лікування госпітальної пневмонії | |
MX2022001449A (es) | Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos. | |
PH12018501585B1 (en) | Novel pyrrolidine derivatives | |
MX2022007874A (es) | Compuestos y derivados de hidroxiestilbeno sustituido, síntesis y usos de los mismos. | |
MX2022005034A (es) | Combinacion farmaceutica y uso de la misma. | |
MX2022005585A (es) | Composiciones farmaceuticas. | |
TWD194419S (zh) | Terminal block | |
TWD193869S (zh) | Safe | |
EA202092495A1 (ru) | МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |